| |
| |
|
| Insider
Information: |
Sepp-Lorenzino Laura |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
81,893 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$2,003,103 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
81,893 |
|
|
| Total
Value |
$2,003,103 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Intellia Therapeutics, Inc. |
NTLA |
|
2024-03-01 |
81,893 |
2021-08-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
13 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Scientific Officer |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
37,966 |
81,893 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Scientific Officer |
• – – |
2024-01-08 |
4 |
AS |
$28.66 |
$65,682 |
D/D |
(2,275) |
43,927 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Scientific Officer |
• – – |
2024-01-03 |
4 |
S |
$29.46 |
$162,973 |
D/D |
(5,532) |
46,202 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Scientific Officer |
• – – |
2024-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,500 |
51,734 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Scientific Officer |
• – – |
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
29,938 |
47,567 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Scientific Officer |
• – – |
2023-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,500 |
22,467 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Scientific Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,816 |
18,631 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Scientific Officer |
• – – |
2022-01-01 |
4 |
S |
$112.25 |
$128,863 |
D/D |
(1,148) |
4,815 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Scientific Officer |
• – – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,500 |
5,963 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Scientific Officer |
• – – |
2021-08-30 |
4 |
AS |
$152.75 |
$15,018,054 |
D/D |
(97,000) |
2,391 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Scientific Officer |
• – – |
2021-08-30 |
4 |
OE |
$13.40 |
$1,359,300 |
D/D |
97,000 |
99,391 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Scientific Officer |
• – – |
2021-08-04 |
4 |
AS |
$135.47 |
$3,594,357 |
D/D |
(26,000) |
2,391 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Scientific Officer |
• – – |
2021-08-04 |
4 |
OE |
$13.40 |
$348,400 |
D/D |
26,000 |
28,391 |
0 |
- |
|
13 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
